Egypt's drug authority, known as the Egyptian Drug Authority, has issued a new decision, number 480 of 2026, regulating the pricing of human medical products. The decision was published in the official Egyptian Gazette on September 23, 2026. The new rules aim to ensure the rights of Egyptian patients, protect the country's pharmaceutical security, and achieve economic and financial balance in the pharmaceutical industry.
The decision outlines the controls and procedures for pricing medical products, with the goal of encouraging investment, protecting competition, and preventing harmful monopolistic practices. The authority seeks to position the Egyptian pharmaceutical market alongside global competitive markets. To achieve this, the authority will consider several factors, including the costs of production and importation, and the addition of a profit margin for producers, importers, distributors, and pharmacists.
A key component of the pricing process is the "cost list," which includes the costs of raw materials, packaging, and other expenses related to the production or importation of medical products. The list will be updated every six months or as needed, based on actual data from manufacturers and importers. The authority will select a sample of companies to provide data on their actual costs, with 50% of the sample changing every six months.
In addition to production costs, the authority will also consider economic variables, such as changes in foreign exchange rates, inflation rates, and interest rates. The authority will take into account any special initiatives by pharmaceutical companies, according to data from the Central Bank of Egypt. These factors will help determine the final prices of medical products.
The new pricing controls are part of the authority's efforts to promote a competitive and transparent pharmaceutical market in Egypt. By regulating prices, the authority aims to ensure that medical products are affordable and accessible to all Egyptians. The decision is also expected to encourage investment in the pharmaceutical industry and promote innovation in the development of new treatments.
The Egyptian pharmaceutical industry is a significant sector in the country's economy, with many local manufacturers and international companies operating in the market. The new pricing controls are expected to have a positive impact on the industry, promoting competition and innovation while protecting the rights of patients and ensuring the quality and safety of medical products.
The authority's decision to regulate pricing is also seen as a step towards aligning the Egyptian pharmaceutical market with international standards and best practices. By adopting a transparent and competitive pricing system, Egypt aims to attract foreign investment and promote the growth of its pharmaceutical industry. The new rules are expected to come into effect soon, with the authority monitoring their implementation and impact on the market.
Key points
- The Egyptian Drug Authority has issued a new decision regulating the pricing of human medical products.
- The new rules aim to ensure the rights of Egyptian patients, protect the country's pharmaceutical security, and achieve economic and financial balance in the pharmaceutical industry.
- The authority will consider several factors, including production costs, economic variables, and profit margins, to determine the final prices of medical products.
